- Home
- ADNT vs ATAI Comparison
ADNT vs ATAI Comparison
Compare ADNT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADNT | ATAI |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ADNT | ATAI |
|---|---|---|
| Price | $21.90 | $3.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $25.41 | $15.88 |
| AVG Volume (30 Days) | 884.2K | ★ 4.4M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $17,439,000,000.00 | $4,089,000.00 |
| Revenue This Year | $2.71 | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | $380.50 | ★ N/A |
| Revenue Growth | 7.56 | ★ 1227.60 |
| 52 Week Low | $16.14 | $2.00 |
| 52 Week High | $27.32 | $6.73 |
Technical Indicators
Market Signals| Indicator | ADNT | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 38.88 |
| Support Level | $18.79 | $3.44 |
| Resistance Level | $23.22 | $4.20 |
| Average True Range (ATR) | 0.98 | 0.31 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 48.62 | 0.42 |
Price Performance
Historical ComparisonAbout ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.